Details of the Drug

General Information of Drug (ID: DMQPZQB)

Drug Name
ALXN2080
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Phase 1 [1]
Cross-matching ID
TTD ID
DKI1A8

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement factor D (CFD) TT8D13I CFAD_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05428696) A Randomized, Double-blind, Placebo-controlled First-in-Human Study of Single and Multiple Doses of ALXN2080 in Healthy Participants. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Alexion